Royal Liverpool Hospital strengthens infection control
Uses Glosair hydrogen peroxide dry mist decontamination technology from ASP
As part of a larger refurbishment project, Royal Liverpool University Hospital has appointed Advanced Sterilization Products (ASP) to perform a deep clean decontamination service using its ASP Glosair technology and supporting the ongoing measures undertaken by staff, cleaners and existing ASP infection prevention solutions used by the hospital.
Glosair technology uses a low concentration hydrogen peroxide dry-mist technology, which operates at room temperature to decontaminate a ward or patient room within three hours of operation time. Its proven efficacy ensures that the safest possible environment is created for patients and healthcare professionals, says ASP, which is a division of Johnson & Johnson Medical in the UK, a developer of instrument sterilisation, disinfection and cleaning technologies.
The easy-to-operate ASP Glosair area decontamination technology is also available for self-service usage by healthcare facilities.
The first ward decontamination at the Royal Liverpool University Hospital has been successfully completed and 14 additional ward decontaminations in multiple hospital sites are scheduled over the coming 10 months.
The Royal Liverpool and Broadgreen University Hospitals NHS Trust has made significant advances in tackling Healthcare Associated Infections (HCAIs) to date and has been recognised as one of the winners in the inaugural NHS Liverpool Quality Awards for Innovation and Improvements.
Diane Wake, director of Infection Prevention and Control at the Royal Liverpool University Hospital, said: “Patients can be reassured that we are continuing to see significant falls in the number of C. Diff and MRSA cases. We have halved our C.Diff rates in the last year. With a greater emphasis on cleaning and cleaning standards, and the use of innovative solutions as provided by ASP, we have made tackling hospital infections our top priority. Our current performance clearly shows that our efforts are making a huge difference; we have gone from being one of the poorest to one of the best performing trusts in the country for infection control.”
While significant progress has been made in recent years to tackle HCAIs, studies conducted by the National Audit Office and the Health Protection Agency have shown that they continue to pose a serious threat to patient safety. Ongoing vigilance is essential to ensuring HCAIs are appropriately prevented and, when required, contained.
ASP offers a range of innovative solutions that are designed to provide a holistic approach to infection prevention.
